MichaelRTranfagliaMD
Psychiatry • Newburyport, MANeuropsychiatry, Psychopharmacology
Medical Director Chief Scientific Officer FRAXA Research Foundation
Dr. Tranfaglia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
45 Pleasant St
Newburyport, MA 01950Phone+1 978-462-1866
Education & Training
University of North Carolina HospitalsResidency, Psychiatry, 1987 - 1991
University of North Carolina at Chapel Hill School of MedicineClass of 1987
Certifications & Licensure
MA State Medical License 1991 - 2025
Publications & Presentations
PubMed
- 45 citationsPDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.Catherine H. Choi, Brian P. Schoenfeld, Eliana D. Weisz, Aaron J. Bell, Daniel B. Chambers
The Journal of Neuroscience. 2015-01-07 - 390 citationsAdvances in the treatment of fragile x SyndromeRandi J Hagerman, Elizabeth Berry-Kravis, Michele Y. Ono, Nicole Tartaglia, Ave M. Lachiewicz
Pediatrics. 2009-01-01 - 269 citationsA pilot open label, single dose trial of fenobam in adults with fragile X syndromeElizabeth Berry-Kravis, David R Hessl, Sarah M. Coffey, Crystal Hervey, Andrea Schneider
Journal of Medical Genetics. 2009-01-06
Press Mentions
Experimental Drug Signals Hope for Fragile X SyndromeOctober 1st, 2024- UK Startup Healx to Begin Clinical Trial on Repositioned Drug for Fragile X SyndromeOctober 20th, 2021
- Study Shows Fragile X Treatment Can Incur Resistance, Suggests Ways Around ItSeptember 29th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
